Qfitlia (Fitusiran) for Hemophilia

Overview

Qfitlia is a medication used to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with hemophilia A or B, with or without inhibitors to factor VIII or IX. It is approved by the U.S. Food and Drug Administration (FDA) for this purpose. The treatment is suitable for individuals who require routine prophylaxis for bleeding episodes. Qfitlia is also known by its drug name, Fitusiran.

Qfitlia belongs to a class of drugs called antithrombin-directed small interfering ribonucleic acids (siRNA). It’s thought to work work by reducing the amount of antithrombin in the blood, which helps to improve the blood clotting process in people with hemophilia.

How do I take it?

Prescribing information states that Qfitlia is administered as an injection under the skin (subcutaneous use). The initial recommended dosing schedule is once every two months. Dosing may be adjusted based on regular monitoring of antithrombin activity to maintain levels between 15 percent and 35 percent. It is important to follow your healthcare provider’s instructions carefully when using this medication.

Side effects

Common side effects of Qfitlia include viral infections, nasopharyngitis (common cold symptoms), and bacterial infections.

Rare but serious side effects may include thrombotic events (blood clots that can block veins or arteries) and acute or recurrent gallbladder disease, which could require surgery. It is important to monitor for signs of gallbladder issues, such as abdominal pain or nausea, and discuss any concerns with a healthcare provider.

For more information about this treatment, visit:

1. Qfitlia (Fitusiran) Injection, for Subcutaneous Use — Genzyme
2. FDA Approves Novel Treatment for Hemophilia A or B, With or Without Factor Inhibitors — U.S. Food and Drug Administration